Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
In a 24-hour water-only fast, the extract reduced hunger ratings by more than 10% [3]
Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks Roche reported positive topline results from its Phase II clinical trial, CT388-103, evaluating CT-388, Roches investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist being developed for the treatment of obesity
It is generally well-tolerated, and researchers have noted a distinct lack of severe adverse reactions or toxicity, even at higher-than-standard doses
Presented for research literature review only Lederer B et al
US$ 23.79
US$ 26.51
US$ 24.90
